Trials / Recruiting
RecruitingNCT06290193
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
A Prospective Randomized Trial of Acute Normovolemic Hemodilution (ANH) in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 86 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a study group. Depending on which group they are in, they will receive either acute normovolemic hemodilution/ANH during surgery or standard surgical management during surgery. The researchers think acute normovolemic hemodilution/ANH may decrease the need for allogenic blood transfusion/ABT in people having primary cytoreductive surgery.
Conditions
- Ovarian Cancer
- Fallopian Tube Carcinoma
- Ovarian Carcinoma
- Peritoneal Carcinoma
- Ovarian Cancer Stage IIIC
- Fallopian Tube Cancer Stage IIIC
- Ovarian Cancer Stage IV
- Fallopian Tube Cancer Stage IV
- Fallopian Tube Cancer
- Peritoneal Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Acute Normovolemic Hemodilution/ANH | For participants randomized to ANH, the volume of blood to be removed will be calculated using an established formula, based on preoperative hemoglobin, target hemoglobin after hemodilution, and the patient's estimated blood volume. |
Timeline
- Start date
- 2024-02-23
- Primary completion
- 2029-02-23
- Completion
- 2029-02-23
- First posted
- 2024-03-04
- Last updated
- 2026-04-01
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06290193. Inclusion in this directory is not an endorsement.